Pfizer Community

Key Takeaways Focus on R&D productivity and strategic investments is expected to boost future revenue and profitability through potential blockbuster drugs and improved net margins. Cost-saving measures and strategic business investments aim to enhance earnings, supporting EPS growth despite challenges from loss of exclusivity events.

Key Takeaways A robust late-stage pipeline, strategic acquisitions, and innovation in biologics and AI-driven R&D position Pfizer for long-term growth in key therapeutic areas. Enhanced global market access and operational efficiencies, including cost savings and digital transformation, are expanding Pfizer's revenue base and improving profitability.

Key Takeaways Increasing competition and reduced utilization of key drugs could pressure Pfizer's revenue, causing underperformance against market expectations. R&D productivity issues and a streamlined investment focus may limit future revenue growth and impact investor confidence.

I think that Pfizer has a strong pipeline. The aquisition of seagen added many new oncology products that will continue to grow by 14% partially offseting the decline on sales of the covid-19 vaccines.